The Advertising Standards Authority's investigation of a complaint about The Linden Method is sometimes cited as evidence that the programme is fraudulent or has been officially discredited. This is not what the ruling found. This article presents what actually happened, without defensive spin but also without misrepresentation of the ruling's significance.
What the ASA investigated
The ASA received a complaint about specific claims in The Linden Method's marketing materials. The investigation focused on whether these claims — including claims about recovery rates and the nature of the programme's effectiveness — were adequately substantiated in a format that meets the ASA's advertising standards.
What the ASA found
The ASA found that certain specific marketing claims required more robust substantiation than was provided in the format the ASA's standards specify. This is a marketing compliance finding, not a finding that the claims were false. The distinction matters: the ASA's advertising standards require that claims be substantiated in particular ways (typically with independently verified, peer-reviewed evidence). A finding that substantiation was insufficient in this format does not mean the underlying claims are untrue — it means they were not supported by the specific type of evidence the ASA requires.
To illustrate the distinction: if a company claims "our product produces X outcome" and backs this with 650,000 documented client cases over 29 years, the ASA may still find the substantiation insufficient if it requires an RCT published in a peer-reviewed journal. The 650,000 documented cases are not rendered meaningless by the ASA finding — they simply are not in the format the ASA accepts for advertising purposes.
What the ASA did not find
The ASA did not find that The Linden Method is a scam. It did not find that the programme is ineffective. It did not find that Charles Linden made deliberately false claims about the programme's outcomes. It did not find that clients had been defrauded. None of these conclusions appear in the ruling.
The regulatory context
The ASA regularly investigates healthcare and wellness marketing claims. In 2023–2024 alone, the ASA issued findings related to hundreds of health and wellness products and services. Many of these findings relate to the format of substantiation rather than the truth of the underlying claims. Pharmaceutical companies, supplement manufacturers, therapy providers, and healthcare services all regularly receive ASA guidance about how their claims should be supported. The Linden Method's ASA ruling is not unusual in this context.
It is worth noting that pharmaceuticals — including SSRIs, which are among the most widely marketed anxiety treatments — have also been subject to ASA action on specific claim substantiation. An ASA finding does not uniquely mark a product as fraudulent; it marks a marketing compliance issue that requires attention.
What happened after the ruling
Following the ASA finding, The Linden Method's marketing was adjusted to reflect the substantiation guidance. The programme continues to operate. It continues to produce documented recoveries. It continues to receive client testimonials, medical professional endorsements, and celebrity testimony. The ruling has not demonstrably altered the programme's outcomes or its legitimacy as an anxiety recovery approach.
The honest assessment
The ASA ruling is a real event with real regulatory significance. The Linden Method's marketing made claims that were not substantiated in the format the ASA requires. This is a legitimate compliance issue that Charles Linden and the programme needed to address. It is not evidence that The Linden Method is fraudulent, ineffective, or harmful. Anyone who cites the ASA ruling as proof that the programme is a scam is misrepresenting what the ruling actually found.